Soleus Capital Management
Latest statistics and disclosures from Soleus Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are KRYS, CELC, TGTX, PODD, NVCR, and represent 34.40% of Soleus Capital Management's stock portfolio.
- Added to shares of these 10 stocks: PODD (+$74M), RIGL (+$72M), INSP (+$61M), ERAS (+$50M), CELC (+$44M), Parabilis Medicines (+$40M), LEGN (+$35M), UNH (+$33M), PALI (+$27M), SUPN (+$24M).
- Started 22 new stock positions in IMUX, WGS, SLN, SYRE, Parabilis Medicines, ERAS, SUPN, AVBP, NKTR, BLTE. ZNTL, Avalyn Pharma, EQ, AORT, LEGN, PRLD, ANL, NVCT, UNH, CAPR, SLDB, PALI.
- Reduced shares in these 10 stocks: TWST (-$115M), KRYS (-$80M), TGTX (-$61M), PRAX (-$51M), ALKS (-$49M), VCEL (-$49M), EWTX (-$41M), MIRM (-$38M), NTRA (-$32M), ALNY (-$30M).
- Sold out of its positions in ANAB, ARWR, COGT, CTMX, DXCM, ETON, Immunic, INBX, JSPR, LBRX. ORKA, RAPP, STAA, TVTX, TYRA, PCVX, ZYME, ICLR.
- Soleus Capital Management was a net seller of stock by $-150M.
- Soleus Capital Management has $2.9B in assets under management (AUM), dropping by 17.53%.
- Central Index Key (CIK): 0001802630
Tip: Access up to 7 years of quarterly data
Positions held by Soleus Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Soleus Capital Management
Soleus Capital Management holds 97 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Krystal Biotech (KRYS) | 12.0 | $349M | -18% | 939k | 371.67 |
|
| Celcuity (CELC) | 6.1 | $178M | +32% | 1.7M | 104.62 |
|
| Tg Therapeutics (TGTX) | 5.5 | $161M | -27% | 2.9M | 54.94 |
|
| Insulet Corporation (PODD) | 5.5 | $160M | +86% | 1.0M | 152.25 |
|
| Novocure Ord Shs (NVCR) | 5.2 | $150M | -5% | 9.9M | 15.15 |
|
| United Therapeutics Corporation (UTHR) | 4.2 | $122M | +20% | 226k | 541.83 |
|
| Inspire Med Sys (INSP) | 3.0 | $86M | +235% | 1.9M | 44.61 |
|
| Rigel Pharmaceuticals (RIGL) | 2.5 | $72M | +18335% | 1.8M | 39.12 |
|
| Biosante Pharmaceuticals (ANIP) | 2.5 | $72M | +5% | 868k | 82.78 |
|
| Beta Bionics (BBNX) | 2.4 | $69M | 4.4M | 15.67 |
|
|
| Vericel (VCEL) | 2.2 | $65M | -42% | 1.5M | 44.49 |
|
| Praxis Precision Medicines I Com New (PRAX) | 2.0 | $59M | -46% | 178k | 334.79 |
|
| Geron Corporation (GERN) | 1.9 | $55M | +3% | 43M | 1.28 |
|
| Alkermes SHS (ALKS) | 1.9 | $54M | -47% | 1.0M | 52.40 |
|
| Erasca (ERAS) | 1.7 | $50M | NEW | 2.7M | 18.32 |
|
| Neuropace (NPCE) | 1.6 | $46M | 2.9M | 15.89 |
|
|
| Progyny (PGNY) | 1.6 | $46M | -22% | 1.6M | 28.83 |
|
| Indivior Pharmaceuticals (INDV) | 1.5 | $44M | -16% | 1.1M | 41.03 |
|
| Parabilis Medicines | 1.4 | $40M | NEW | 1.5M | 27.37 |
|
| Edap Tms S A Sponsored Adr (FOCL) | 1.3 | $38M | 7.3M | 5.18 |
|
|
| Globus Med Cl A (GMED) | 1.3 | $37M | -35% | 469k | 79.01 |
|
| Arcus Biosciences Incorporated (RCUS) | 1.2 | $36M | +158% | 1.2M | 30.83 |
|
| Syndax Pharmaceuticals (SNDX) | 1.2 | $36M | -5% | 1.6M | 21.86 |
|
| Nurix Therapeutics (NRIX) | 1.2 | $36M | +56% | 1.5M | 24.26 |
|
| Legend Biotech Corp Sponsored Ads (LEGN) | 1.2 | $35M | NEW | 1.2M | 28.88 |
|
| Jade Biosciences Com New (JBIO) | 1.2 | $35M | +94% | 1.6M | 22.22 |
|
| UnitedHealth (UNH) | 1.1 | $33M | NEW | 80k | 415.63 |
|
| Avalo Therapeutics Com New (AVTX) | 1.1 | $31M | +274% | 1.7M | 18.48 |
|
| Urogen Pharma (URGN) | 1.1 | $31M | +14% | 830k | 36.80 |
|
| Mbx Biosciences (MBX) | 1.0 | $28M | +188% | 515k | 55.20 |
|
| Palisade Bio (PALI) | 0.9 | $27M | NEW | 13M | 2.09 |
|
| Pharvaris N V (PHVS) | 0.9 | $25M | +4% | 731k | 34.58 |
|
| Organogenesis Hldgs (ORGO) | 0.8 | $25M | 10M | 2.43 |
|
|
| Supernus Pharmaceuticals (SUPN) | 0.8 | $24M | NEW | 520k | 46.51 |
|
| Procept Biorobotics Corp (PRCT) | 0.8 | $23M | +526% | 1.0M | 22.58 |
|
| Tango Therapeutics (TNGX) | 0.8 | $22M | +57% | 709k | 31.26 |
|
| Inhibikase Therapeutics Com New (IKT) | 0.8 | $22M | 11M | 2.03 |
|
|
| Trevi Therapeutics (TRVI) | 0.8 | $22M | -27% | 1.2M | 18.65 |
|
| BioMarin Pharmaceutical (BMRN) | 0.7 | $22M | -42% | 376k | 57.22 |
|
| Livanova SHS (LIVN) | 0.7 | $21M | -56% | 255k | 82.23 |
|
| Argenx Se Sponsored Adr (ARGX) | 0.6 | $19M | +470% | 20k | 927.77 |
|
| Nuvectis Pharma (NVCT) | 0.6 | $18M | NEW | 1.0M | 18.39 |
|
| Capricor Therapeutics Com New (CAPR) | 0.6 | $18M | NEW | 762k | 24.08 |
|
| Edgewise Therapeutics (EWTX) | 0.6 | $18M | -68% | 451k | 40.63 |
|
| Prelude Therapeutics (PRLD) | 0.6 | $18M | NEW | 3.4M | 5.33 |
|
| Xenon Pharmaceuticals (XENE) | 0.6 | $16M | -8% | 267k | 60.36 |
|
| C4 Therapeutics Com Stk (CCCC) | 0.5 | $16M | -11% | 3.4M | 4.67 |
|
| Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA) | 0.5 | $16M | -52% | 246k | 63.95 |
|
| Orthopediatrics Corp. (KIDS) | 0.5 | $14M | +18% | 732k | 19.13 |
|
| Avalyn Pharmaceuticals Com Shs | 0.5 | $14M | NEW | 419k | 32.92 |
|
| Biodesix (BDSX) | 0.5 | $13M | +40% | 586k | 22.55 |
|
| Spyre Therapeutics Com New (SYRE) | 0.4 | $13M | NEW | 147k | 88.78 |
|
| Twist Bioscience Corp (TWST) | 0.4 | $11M | -91% | 105k | 102.88 |
|
| Vir Biotechnology (VIR) | 0.4 | $10M | -50% | 1.0M | 10.19 |
|
| Alnylam Pharmaceuticals (ALNY) | 0.3 | $9.9M | -74% | 33k | 301.03 |
|
| Immunovant (IMVT) | 0.3 | $9.7M | +9% | 252k | 38.53 |
|
| Insmed Com Par $.01 (INSM) | 0.3 | $9.6M | +780% | 90k | 106.62 |
|
| Septerna (SEPN) | 0.3 | $9.2M | 275k | 33.49 |
|
|
| Sophia Genetics Sa Ordinary Shares (SOPH) | 0.3 | $9.0M | -15% | 1.6M | 5.77 |
|
| Nektar Therapeutics Com New (NKTR) | 0.3 | $9.0M | NEW | 128k | 69.81 |
|
| Mirum Pharmaceuticals (MIRM) | 0.3 | $8.8M | -81% | 75k | 117.07 |
|
| CryoLife (AORT) | 0.3 | $8.7M | NEW | 388k | 22.47 |
|
| Tandem Diabetes Care Com New (TNDM) | 0.3 | $8.7M | -26% | 575k | 15.09 |
|
| Enliven Therapeutics (ELVN) | 0.3 | $8.4M | -28% | 166k | 50.75 |
|
| Sionna Therapeutics (SION) | 0.3 | $7.8M | -39% | 178k | 43.99 |
|
| Belite Bio Sponsored Ads (BLTE) | 0.3 | $7.8M | NEW | 51k | 153.99 |
|
| Cerus Corporation (CERS) | 0.3 | $7.3M | -76% | 2.5M | 2.92 |
|
| Silence Therapeutics Ads (SLN) | 0.2 | $6.9M | NEW | 630k | 10.98 |
|
| Immunic Com New (IMUX) | 0.2 | $6.9M | NEW | 450k | 15.37 |
|
| Adagio Therapeutics (IVVD) | 0.2 | $6.7M | 7.7M | 0.87 |
|
|
| Merck & Co (MRK) | 0.2 | $6.4M | -75% | 50k | 128.50 |
|
| Relmada Therapeutics (RLMD) | 0.2 | $5.8M | 842k | 6.92 |
|
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.2 | $5.7M | +33% | 107k | 53.67 |
|
| Evolus (EOLS) | 0.2 | $5.7M | -63% | 822k | 6.94 |
|
| Adlai Nortye Sponsored Ads (ANL) | 0.2 | $4.7M | NEW | 406k | 11.50 |
|
| Zentalis Pharmaceuticals (ZNTL) | 0.2 | $4.6M | NEW | 950k | 4.85 |
|
| Karyopharm Therapeutics Com New (KPTI) | 0.1 | $4.3M | 440k | 9.77 |
|
|
| Context Therapeutics (CNTX) | 0.1 | $3.9M | 7.1M | 0.55 |
|
|
| Pulmonx Corp (LUNG) | 0.1 | $3.6M | 2.8M | 1.30 |
|
|
| Sab Biotherapeutics Com New (SABS) | 0.1 | $3.5M | -14% | 900k | 3.90 |
|
| Tectonic Therapeutic (TECX) | 0.1 | $3.5M | -16% | 102k | 34.38 |
|
| Axogen (AXGN) | 0.1 | $2.6M | -91% | 57k | 46.19 |
|
| Satellos Bioscience (MSLE) | 0.1 | $2.4M | -24% | 314k | 7.78 |
|
| Arrivent Biopharma (AVBP) | 0.1 | $1.7M | NEW | 50k | 34.74 |
|
| Corcept Therapeutics Incorporated (CORT) | 0.1 | $1.7M | -93% | 20k | 86.95 |
|
| Solid Biosciences Com New (SLDB) | 0.1 | $1.5M | NEW | 150k | 9.99 |
|
| Veracyte (VCYT) | 0.1 | $1.5M | -92% | 25k | 58.73 |
|
| Cullinan Oncology (CGEM) | 0.0 | $911k | -87% | 50k | 18.21 |
|
| Inspiremd (NSPR) | 0.0 | $732k | 1.0M | 0.70 |
|
|
| Genedx Holdings Corp Com Cl A (WGS) | 0.0 | $687k | NEW | 10k | 68.65 |
|
| Iovance Biotherapeutics (IOVA) | 0.0 | $624k | -85% | 150k | 4.16 |
|
| Larimar Therapeutics (LRMR) | 0.0 | $574k | -82% | 188k | 3.05 |
|
| Cg Oncology (CGON) | 0.0 | $355k | -75% | 5.0k | 71.05 |
|
| Quoin Pharmaceuticals Sponsored Ads (QNRX) | 0.0 | $352k | 73k | 4.84 |
|
|
| Equillium (EQ) | 0.0 | $288k | NEW | 90k | 3.20 |
|
| Natera (NTRA) | 0.0 | $272k | -99% | 1.0k | 271.45 |
|
| Neogenomics Com New (NEO) | 0.0 | $146k | -94% | 10k | 14.59 |
|
Past Filings by Soleus Capital Management
SEC 13F filings are viewable for Soleus Capital Management going back to 2019
- Soleus Capital Management 2026 Q2 filed Aug. 11, 2026
- Soleus Capital Management 2026 Q1 filed May 14, 2026
- Soleus Capital Management 2025 Q4 filed Feb. 12, 2026
- Soleus Capital Management 2025 Q3 filed Nov. 14, 2025
- Soleus Capital Management 2025 Q2 filed Aug. 15, 2025
- Soleus Capital Management 2025 Q1 filed May 15, 2025
- Soleus Capital Management 2024 Q4 filed Feb. 14, 2025
- Soleus Capital Management 2024 Q3 filed Nov. 14, 2024
- Soleus Capital Management 2024 Q2 filed Aug. 14, 2024
- Soleus Capital Management 2024 Q1 filed May 15, 2024
- Soleus Capital Management 2023 Q4 filed Feb. 14, 2024
- Soleus Capital Management 2023 Q3 filed Nov. 14, 2023
- Soleus Capital Management 2023 Q2 filed Aug. 14, 2023
- Soleus Capital Management 2023 Q1 filed May 15, 2023
- Soleus Capital Management 2022 Q4 filed Feb. 14, 2023
- Soleus Capital Management 2022 Q3 filed Nov. 14, 2022